Mycoplasma Testing Market Share

North American Market Statistics

The North America mycoplasma testing market is poised to be the largest with a share of about 37% by the end of 2037. The presence of various biotech and pharmaceutical companies and increased investment in R&D will push the formation of new drugs and antibodies, recombinant proteins, and cell-based therapies. The need for mycoplasma testing increases correspondingly to ensure the safety and quality of these products. The Department of Health and Human Services in the United States will put USD 40 million to broaden the role of biomanufacturing in the development of active pharmaceutical ingredients (APIs), antibiotics, and essential pharmaceuticals.

APAC Market Analysis

The Asia Pacific mycoplasma testing market is estimated to be the second largest, registering a share of about 26% over the forecast period. The increased knowledge of the effects of infectious substances, as well as regulatory restrictions enforced by healthcare organizations to improve biosafety quality, are driving the demand for mycoplasma testing. WHO's Regional Office for South East Asia (SEARO) arranged two regional trainings to assist biosafety, concentrating on infectious material shipping, and bio-risk assessment.

European Market Forecast

Further, the mycoplasma testing market in Europe is projected to hold a notable share between 2023 and 2037. The market growth in the region is due to strict adherence to good laboratory practices (GLP), and good manufacturing practices (GMP) by all the biotech and pharma companies. Hence, mycoplasma testing is considered an essential component of these practices to ensure product safety.